PLANNING AND EVALUATION The LCCC internal and external advisory groups provided invaluable guidance in planning and evaluation of all the major initiatives and includes: ? The Senior Leadership Team, which is composed of the Director, Deputy Director and Associate Directors and meets weekly to evaluate progress in strategic LCCC initiatives. ? The Program Planning Committee, which meets monthly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, as well as the Senior Leadership Team. ? The Internal Advisory Board, comprised of institutional leaders including the Chancellor; Dean of the College of Arts and Sciences, Deans of the Schools of Medicine, Pharmacy, and Public Health and external advisors, and meets with the Director at least quarterly. ? The Scientific Advisory Board (SAB), which is comprised of expert external advisors, and which was expanded with the addition of two new members in 2018/19 to provide additional expertise in specific areas such as community outreach and engagement and clinical trials. There are now 14 members on the SAB with complementary expertise in basic, clinical, translational, and population sciences and administration. The SAB meets at least annually at the UNC LCCC. ? The Community Advisory Board (CAB), the 12 membered CAB meets quarterly with the Director and COE Leadership. The CAB is geographically, racially and ethnically representative of our catchment area (the state of North Carolina) and offers a variety of important perspectives and constituencies, including cancer survivors and caregivers, community and faith-based organizations, rural and urban areas, state and non-profit agencies, and under-represented minorities. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that LCCC most effectively set priorities and pursues objectives that promote basic, clinical, prevention and translational research at the Center. With careful planning and critical input from advisory groups, the Director initiated a new 5 year strategic planning process, reorganized operating committees, continued significant recruitment, launched new population-based studies, strengthened community outreach efforts, and expanded immunotherapy and GMP infrastructure.
Showing the most recent 10 out of 1525 publications
